Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease (2018) Gu JM, Yuam S, Sim D, Abe K, Liu P, Rosenbruch M, Bringmann P, Kauser K Experimental Hematology 2018

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (2017) Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM and Butterfield LH J Immunother Cancer

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles (2017) Loges S, Gjertsen BT, Heuser M, Chromik J, Ben-Batalla I, Akyuz N, Micklem D, Brown A, Lorens J, Yule M, Kebenko M, Janning M, Binder M, Fiedler W, Cortes J Blood

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (Am0010) in Patients with Advanced Solid Tumors (2016) Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR Journal of Clinical Oncology

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M Clinical Cancer Research

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) Sznol M, Fishman M, Escudier B, McDermott DF, Kluger H, Stadler WM, Perez-Gracia J, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Drake CG, Young TC, Chasalow SD, Ross-MacDonald P, Simon JS, Walker D, Choueiri TK J Immunother Cancer

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. (2014) Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. Nature. 2014 Nov 26;515(7528):558-62. doi: 10.1038/nature13904.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. (2014) Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Nature. 2014 Nov 26;515(7528):563-7. doi: 10.1038/nature14011.